281 related articles for article (PubMed ID: 16965845)
1. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
Foronda NM; Fowles J; Smith N; Taylor M; Temple W
Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
[TBL] [Abstract][Full Text] [Related]
2. The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080).
Foronda NM; Fowles J; Smith N; Taylor M; Temple W; Darlington C
Regul Toxicol Pharmacol; 2007 Feb; 47(1):29-36. PubMed ID: 17030370
[TBL] [Abstract][Full Text] [Related]
3. Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology.
Hwang M; Yoon E; Kim J; Jang DD; Yoo TM
Regul Toxicol Pharmacol; 2009 Mar; 53(2):102-6. PubMed ID: 19133308
[TBL] [Abstract][Full Text] [Related]
4. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
Sand S; Victorin K; Filipsson AF
J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
[TBL] [Abstract][Full Text] [Related]
5. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
6. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
7. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
Slob W; Moerbeek M; Rauniomaa E; Piersma AH
Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
Izadi H; Grundy JE; Bose R
Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
[TBL] [Abstract][Full Text] [Related]
9. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
10. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose.
Barnes DG; Daston GP; Evans JS; Jarabek AM; Kavlock RJ; Kimmel CA; Park C; Spitzer HL
Regul Toxicol Pharmacol; 1995 Apr; 21(2):296-306. PubMed ID: 7644719
[TBL] [Abstract][Full Text] [Related]
11. Development of an occupational exposure limit for n-propylbromide using benchmark dose methods.
Stelljes ME; Wood RR
Regul Toxicol Pharmacol; 2004 Oct; 40(2):136-50. PubMed ID: 15450717
[TBL] [Abstract][Full Text] [Related]
12. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
13. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
Davis JA; Gift JS; Zhao QJ
Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
[TBL] [Abstract][Full Text] [Related]
14. Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate.
Reiss R; Gaylor D
Regul Toxicol Pharmacol; 2005 Oct; 43(1):55-65. PubMed ID: 16099569
[TBL] [Abstract][Full Text] [Related]
15. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
Sand S; von Rosen D; Victorin K; Filipsson AF
Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
[TBL] [Abstract][Full Text] [Related]
16. Relation between benchmark dose and no-observed-adverse-effect level in clinical research: effects of daily alcohol intake on blood pressure in Japanese salesmen.
Dakeishi M; Murata K; Tamura A; Iwata T
Risk Anal; 2006 Feb; 26(1):115-23. PubMed ID: 16492185
[TBL] [Abstract][Full Text] [Related]
17. Quantalization of continuous data for benchmark dose estimation.
Gaylor DW
Regul Toxicol Pharmacol; 1996 Dec; 24(3):246-50. PubMed ID: 8975754
[TBL] [Abstract][Full Text] [Related]
18. Procedures for calculating benchmark doses for health risk assessment.
Gaylor D; Ryan L; Krewski D; Zhu Y
Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
[TBL] [Abstract][Full Text] [Related]
19. Calculation of benchmark doses for reproductive and developmental toxicity observed after exposure to isopropanol.
Allen B; Gentry R; Shipp A; Van Landingham C
Regul Toxicol Pharmacol; 1998 Aug; 28(1):38-44. PubMed ID: 9784431
[TBL] [Abstract][Full Text] [Related]
20. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
